|Over a week ago|
Talaris Therapeutics to present on FCR001 at American Transplant Congress » 07:1106/0306/03/21
Talaris Therapeutics announced upcoming presentations of data from the company's Phase 2 study of FCR001 at the American Transplant Congress taking place virtually June 4-9, 2021. The accepted oral presentation includes data on the company's analysis of peripheral blood chimerism as a biomarker for transplantation tolerance. Phase 2 data indicate that one, three, six, and 12-month chimerism levels are highly correlated with each other and increasingly predictive over time of the ability to withdraw immunosuppression at one year, suggesting that whole blood and T-cell chimerism could be a valuable surrogate marker of the ability to discontinue immunosuppression at one year without rejection of the transplanted organ. In addition, a poster will report on the long-term follow-up of the company's Phase 2 trial in living donor kidney transplant recipients. Among the 37 subjects administered FCR001, 26 displayed durable chimerism allowing for full withdrawal of immunosuppression, and updated data show that all stable chimeric subjects remain rejection-free with a minimum follow-up of four years and the longest follow-up of almost 12 years.
Talaris Therapeutics initiated with an Outperform at SVB Leerink » 08:4506/0106/01/21
SVB Leerink analyst Mani…
SVB Leerink analyst Mani Foroohar initiated coverage of Talaris Therapeutics with an Outperform rating and $21 price target. With strong clinical data, long follow-up, and near-term catalysts in lead indication living donor kidney transplant, and compelling expansion opportunities in autoimmune indications to support the story long-term, the analyst sees Talaris Therapeutics as "meaningfully undervalued."
Evercore starts Talaris Therapeutics at Outperform with $35 price target » 07:0006/0106/01/21
As previously reported,…
As previously reported, Evercore ISI analyst Josh Schimmer initiated coverage of Talaris Therapeutics with an Outperform rating and $35 price target. The company's platform for enabling tolerance of transplanted organs is "novel and powerful," said Schimmer, who adds that he sees "little relevant competition on the horizon." He projects peak revenue approaching $1B in 2028 for Talaris, even with a pricing assumption he calls "quite conservative."
Talaris Therapeutics initiated with an Outperform at Evercore ISI » 06:2206/0106/01/21
Evercore ISI analyst Josh…
Evercore ISI analyst Josh Schimmer initiated coverage of Talaris Therapeutics with an Outperform rating and $35 price target.
Talaris Therapeutics initiated with a Buy at Guggenheim » 06:1806/0106/01/21
Guggenheim analyst Debjit…
Guggenheim analyst Debjit Chattopadhyay initiated coverage of Talaris Therapeutics with a Buy rating and $26 price target.
Talaris Therapeutics initiated with an Overweight at Morgan Stanley » 06:1606/0106/01/21
Morgan Stanley analyst…
Morgan Stanley analyst Vikram Purohit initiated coverage of Talaris Therapeutics with an Overweight rating and $35 price target. Talaris is developing FCR001 to help wean kidney transplant patients off chronic immunosuppression, Purohit tells investors in a research note. The analyst sees "high odds of success" for the Phase III study currently underway and believes positive interim updates could drive Talaris shares "significantly higher."
Opening Day: ZipRecruiter, FIGS soar in market debuts » 08:5905/2905/29/21
SQSP, COIN, CNTA, OMIC, FIGS, RBLX, DAWN, ZIP, PAY, FLYW, FSBC, HNST, BWMN, ANEB, TALS, WDH, QNIU, SVFD, RGCB, CMSL, WKME, AMZN, F, GS, JPM, MS, UBER, LYFT, SAFO
Shares of ZipRecruiter…
|Over a month ago|
Talaris Therapeutics director buys 235K shares of common stock » 20:4005/1105/11/21
In a regulatory filing,…
In a regulatory filing, Talaris Therapeutics disclosed that its board member Sandip Agarwala bought 235K shares of common stock on May 11th in a total transaction size of about $4M.
Opening Day: Jessica Alba's Honest Company raises over $400M in IPO » 10:2105/0805/08/21
SBUX, SAFO, COST, TGT, WDH, TALS, ANEB, BWMN, HNST, FSBC, ALF, APP, GLBE, SQSP, QNIU, SVFD, RGCB, CMSL, UBER, LYFT, BX
The consumer goods…
Talaris Therapeutics opens at $17.25, IPO priced at $17 per share 12:2005/0705/07/21